EU/3/15/1457: Orphan designation for the treatment of tenosynovial giant cell tumour, localised and diffuse type

[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride

Overview

On 19 March 2015, orphan designation (EU/3/15/1457) was granted by the European Commission to Daiichi Sankyo Development Ltd, United Kingdom, for [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride for the treatment of tenosynovial giant cell tumour, localised and diffuse type.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.

Key facts

Active substance
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride
Intended use
Treatment of tenosynovial giant cell tumour, localised and diffuse type
Orphan designation status
Withdrawn
EU designation number
EU/3/15/1457
Date of designation
19/03/2015
Sponsor
Daiichi Sankyo Development Ltd
Chiltern Place
Chalfont Park
Gerrards Cross
Buckinghamshire SL9 0BG
United Kingdom
Tel. +44 (0)1753 893 600
Fax +44 (0)1753 899 107
E-mail: info@dsd-eu.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating